<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546909</url>
  </required_header>
  <id_info>
    <org_study_id>RVX01C</org_study_id>
    <nct_id>NCT01546909</nct_id>
  </id_info>
  <brief_title>Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE</brief_title>
  <official_title>Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES

        -  To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or
           DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and
           poliovirus types 1, 2 and 3

        -  To describe one month after a booster dose of TETRAVAC-ACELLULAIRE the immune responses
           against diphtheria, tetanus, and poliovirus types 1, 2 and 3

      SECONDARY OBJECTIVES

        -  To describe other parameters of the antibody persistence against diphtheria, tetanus and
           poliomyelitis antigens

        -  To describe other parameters of the immune responses to diphtheria, tetanus and
           poliomyelitis antigens one month after a booster dose of TETRAVAC-ACELLULAIRE

        -  To describe the safety profile of a booster dose of TETRAVAC-ACELLULAIRE
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-diphtheria concentration ≥0.01 IU/mL</measure>
    <time_frame>Pre-booster dose (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-tetanus concentration ≥0.01 IU/mL</measure>
    <time_frame>Pre-booster dose (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 1 titer ≥ 8 (1/dilution)</measure>
    <time_frame>Pre-booster dose (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 2 titer ≥ 8 (1/dilution)</measure>
    <time_frame>Pre-booster dose (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 3 titer ≥ 8 (1/dilution)</measure>
    <time_frame>Pre-booster dose (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-diphtheria concentration ≥0.1 IU/mL</measure>
    <time_frame>1 month post-booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-tetanus concentration ≥0.1 IU/mL</measure>
    <time_frame>1 month post-booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 1 titer ≥8 (1/dilution)</measure>
    <time_frame>1 month post-booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 2 titer ≥8 (1/dilution)</measure>
    <time_frame>1 month post-booster dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polio type 3 titer ≥8 (1/dilution)</measure>
    <time_frame>1 month post-booster dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer for diphtheria</measure>
    <time_frame>Pre-booster (Day 0) and 1 month post-booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer for tetanus</measure>
    <time_frame>Pre-booster (Day 0) and 1 month post-booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer for polio type 1</measure>
    <time_frame>Pre-booster (Day 0) and 1 month post-booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer for polio type 2</measure>
    <time_frame>Pre-booster (Day 0) and 1 month post-booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer for polio type 3</measure>
    <time_frame>Pre-booster (Day 0) and 1 month post-booster dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited injection site and solicited systemic reactions</measure>
    <time_frame>From Day 0 to Day 7 post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection site reactions and unsolicited systemic adverse events</measure>
    <time_frame>From Day 0 to Day 28 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From signature of informed consent up to last study visit of the subject</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>TETRAVAC-ACELLULAIRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria, tetanus, polio and pertussis vaccination</intervention_name>
    <description>1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0</description>
    <arm_group_label>TETRAVAC-ACELLULAIRE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy child 11 to 13 years of age previously vaccinated in Study F05-TdI-301

        Exclusion Criteria:

          -  Immunization against diphtheria, tetanus, pertussis and/or poliomyelitis beyond Study
             F05-TdI-301

          -  Previous clinical or bacteriological diagnosis of diphtheria, tetanus, pertussis or
             poliomyelitis

          -  Known or suspected immune dysfunction

          -  Receipt of medications / vaccination that may interfere with study assessments

          -  Known true hypersensitivity to any of the vaccine components or to a vaccine
             containing the same substances

          -  Known personal history of encephalopathy, seizure disorder or progressive, evolving or
             unstable neurological condition

          -  Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular
             injection

          -  Any medical condition that might interfere with the evaluation of the study objectives

          -  Febrile illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPMSD Investigational Site 120</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 103</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 155</name>
      <address>
        <city>Asnieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 125</name>
      <address>
        <city>Bersee</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 121</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 141</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 124</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 161</name>
      <address>
        <city>Blois</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 194</name>
      <address>
        <city>Boulogne Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 148</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 117</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 147</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 135</name>
      <address>
        <city>Chalons En Champagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 163</name>
      <address>
        <city>Champdeniers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 145</name>
      <address>
        <city>Chigny Les Roses</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 157</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 101</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 160</name>
      <address>
        <city>Collombey Les Belles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 162</name>
      <address>
        <city>Collombey Les Belles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 139</name>
      <address>
        <city>DAX</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 193</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 106</name>
      <address>
        <city>Essey Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 123</name>
      <address>
        <city>Essey Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 164</name>
      <address>
        <city>Essey Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 136</name>
      <address>
        <city>Floirac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 114</name>
      <address>
        <city>Frouard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 150</name>
      <address>
        <city>Haguenau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 113</name>
      <address>
        <city>Illkirch Graffenstaden</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 197</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 198</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 107</name>
      <address>
        <city>Lingolsheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 115</name>
      <address>
        <city>Louverne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 140</name>
      <address>
        <city>Manduel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 116</name>
      <address>
        <city>Maromme</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 153</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 134</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 129</name>
      <address>
        <city>Nogent Sur Marne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 133</name>
      <address>
        <city>Ostwald</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 128</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 130</name>
      <address>
        <city>Pont A Mousson</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 151</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 102</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 110</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 199</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 152</name>
      <address>
        <city>Saint Ouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

